Trial · NCT01263470
Outcomes17
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Glycosylated Hemoglobin (Week 12). | Baseline and Week 12. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 2). | Baseline and Week 2. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 4). | Baseline and Week 4. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Glycosylated Hemoglobin (Week 8). | Baseline and Week 8. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | percentage of Glycosylated Hemoglobin | MEAN |
| SECONDARY | Change From Baseline in Fasting Plasma Glucose (Week 2). | Baseline and Week 2 | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Fasting Plasma Glucose (Week 4). | Baseline and Week 4. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Fasting Plasma Glucose (Week 8). | Baseline and Week 8. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Fasting Plasma Glucose (Week 12). | Baseline and Week 12. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Fasting C-peptide (Week 2). | Baseline and Week 2. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | ng/mL | MEAN |
| SECONDARY | Change From Baseline in Fasting C-peptide (Week 4). | Baseline and Week 4. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | ng/mL | MEAN |
| SECONDARY | Change From Baseline in Fasting C-peptide (Week 8). | Baseline and Week 8. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | ng/mL | MEAN |
| SECONDARY | Change From Baseline in Fasting C-peptide (Week 12). | Baseline and Week 12. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | ng/mL | MEAN |
| SECONDARY | Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value). | Baseline and Week 12. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing - Area Under the Curve at 2 Hours (AUC (0-2)). | Baseline and Week 12. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | mg·hr/dL | MEAN |
| SECONDARY | Change From Baseline in Insulin Measured by Meal Tolerance Testing - Area Under the Curve at 2 Hours (AUC(0-2)). | Baseline and Week 12 | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | μU·hr/mL | MEAN |
| SECONDARY | Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2). | Baseline and Week 12. | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | ng·hr/mL | MEAN |
| SECONDARY | Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)). | Baseline and Week 12 | Analysis based on last observation carried forward, where the last postbaseline double-blind observed value is carried forward and used for all subsequent scheduled time points where data is missing. Values are from the Full Analysis Set. | pg·hr/mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01263470/outcomes